Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies : the prospective non-interventional SMARTrial
© 2023. The Author(s)..
Ex vivo drug response profiling is a powerful tool to study genotype-drug response associations and is being explored as a tool set for precision medicine in cancer. Here we conducted a prospective non-interventional trial to investigate feasibility of ex vivo drug response profiling for treatment guidance in hematologic malignancies (SMARTrial, NCT03488641 ). The primary endpoint to provide drug response profiling reports within 7 d was met in 91% of all study participants (N = 80). Secondary endpoint analysis revealed that ex vivo resistance to chemotherapeutic drugs predicted chemotherapy treatment failure in vivo. We confirmed the predictive value of ex vivo response to chemotherapy in a validation cohort of 95 individuals with acute myeloid leukemia treated with daunorubicin and cytarabine. Ex vivo drug response profiles improved ELN-22 risk stratification in individuals with adverse risk. We conclude that ex vivo drug response profiling is clinically feasible and has the potential to predict chemotherapy response in individuals with hematologic malignancies beyond clinically established genetic markers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Nature cancer - 4(2023), 12 vom: 02. Dez., Seite 1648-1659 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liebers, Nora [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
04079A1RDZ |
|---|
| Anmerkungen: |
Date Completed 27.12.2023 Date Revised 15.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s43018-023-00645-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362795835 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362795835 | ||
| 003 | DE-627 | ||
| 005 | 20240416232313.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s43018-023-00645-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1377.xml |
| 035 | |a (DE-627)NLM362795835 | ||
| 035 | |a (NLM)37783805 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liebers, Nora |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies |b the prospective non-interventional SMARTrial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.12.2023 | ||
| 500 | |a Date Revised 15.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Ex vivo drug response profiling is a powerful tool to study genotype-drug response associations and is being explored as a tool set for precision medicine in cancer. Here we conducted a prospective non-interventional trial to investigate feasibility of ex vivo drug response profiling for treatment guidance in hematologic malignancies (SMARTrial, NCT03488641 ). The primary endpoint to provide drug response profiling reports within 7 d was met in 91% of all study participants (N = 80). Secondary endpoint analysis revealed that ex vivo resistance to chemotherapeutic drugs predicted chemotherapy treatment failure in vivo. We confirmed the predictive value of ex vivo response to chemotherapy in a validation cohort of 95 individuals with acute myeloid leukemia treated with daunorubicin and cytarabine. Ex vivo drug response profiles improved ELN-22 risk stratification in individuals with adverse risk. We conclude that ex vivo drug response profiling is clinically feasible and has the potential to predict chemotherapy response in individuals with hematologic malignancies beyond clinically established genetic markers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Cytarabine |2 NLM | |
| 650 | 7 | |a 04079A1RDZ |2 NLM | |
| 650 | 7 | |a Daunorubicin |2 NLM | |
| 650 | 7 | |a ZS7284E0ZP |2 NLM | |
| 650 | 7 | |a Antibiotics, Antineoplastic |2 NLM | |
| 650 | 7 | |a Antimetabolites, Antineoplastic |2 NLM | |
| 700 | 1 | |a Bruch, Peter-Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Terzer, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Hernandez-Hernandez, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Paramasivam, Nagarajan |e verfasserin |4 aut | |
| 700 | 1 | |a Fitzgerald, Donnacha |e verfasserin |4 aut | |
| 700 | 1 | |a Altmann, Heidi |e verfasserin |4 aut | |
| 700 | 1 | |a Roider, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Kolb, Carolin |e verfasserin |4 aut | |
| 700 | 1 | |a Knoll, Mareike |e verfasserin |4 aut | |
| 700 | 1 | |a Lenze, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Platzbecker, Uwe |e verfasserin |4 aut | |
| 700 | 1 | |a Röllig, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Baldus, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Serve, Hubert |e verfasserin |4 aut | |
| 700 | 1 | |a Bornhäuser, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Hübschmann, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Müller-Tidow, Carsten |e verfasserin |4 aut | |
| 700 | 1 | |a Stölzel, Friedrich |e verfasserin |4 aut | |
| 700 | 1 | |a Huber, Wolfgang |e verfasserin |4 aut | |
| 700 | 1 | |a Benner, Axel |e verfasserin |4 aut | |
| 700 | 1 | |a Zenz, Thorsten |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Junyan |e verfasserin |4 aut | |
| 700 | 1 | |a Dietrich, Sascha |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature cancer |d 2020 |g 4(2023), 12 vom: 02. Dez., Seite 1648-1659 |w (DE-627)NLM307030067 |x 2662-1347 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2023 |g number:12 |g day:02 |g month:12 |g pages:1648-1659 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s43018-023-00645-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2023 |e 12 |b 02 |c 12 |h 1648-1659 | ||